Hematology News

Concizumab appeared safe and demonstrated clinical proof of concept in preventing bleeds among patients with hemophilia A and hemophilia A or B with inhibitors, according to results of two phase 2 trials published in Blood.

The FDA approved rivaroxaban for the prevention of venous thromboembolism among acutely ill hospitalized patients who are at risk for blood clots but not at high risk for bleeding, according to a press release from the agent’s manufacturer.

World Thrombosis Day is observed on Oct. 13.

A novel biocompatible “lab-on-a-chip” device may help accelerate the discovery and development of new antiplatelet therapies, according to research published in Analytical Chemistry.

The FDA awarded 12 grants worth more than $15 million to fund clinical trials of medical products intended to treat patients with rare diseases.

Three scientists — two from the United States and one from England — the Nobel Prize in Medicine or Physiology for their discoveries of how cells sense and adapt to oxygen availability.

ASH awarded $150,000 each to 19 investigators through the society’s bridge grant program, designed to sustain promising hematologic research proposals that are not funded through NIH.

Direct oral anticoagulants should be used to prevent venous thromboembolism among certain patients with cancer, as well as to treat those who develop blood clots, according to updated ASCO recommendations published in Journal of Clinical Oncology.

September is National Sickle Cell Awareness Month.

Higher estimated cardiorespiratory fitness levels appeared associated with a lower risk for venous thromboembolism, according to results of a population-based cohort study published in Journal of Thrombosis and Haemostasis.